TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03312101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
Study: NCT05651984

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison between communication board and eye tracking
Description: The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison between communication board and eye tracking
Description: The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
Study: NCT05136040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Two Different Low-Doses Of Isobaric Bupivacaine ( Group İzobarik bupivakain (5 mg) + fentanil and Group İzobarik bupivakain (7 mg)+ fentanyl ) were administered to the subarachnoid space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Two Different Low-Doses Of Isobaric Bupivacaine ( Group İzobarik bupivakain (5 mg) + fentanil and Group İzobarik bupivakain (7 mg)+ fentanyl ) were administered to the subarachnoid space
Study: NCT02635529

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD+ DFDBA
Description: After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD+ DFDBA+ AM
Description: After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
Study: NCT01690819

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ventilatory Strategy
Description: The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protective Ventilatory Strategy
Description: The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
Study: NCT04039763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: Realtime Continous Glucose Monitoring

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Self monitoring of blood glucose
Description: Finger prick self monitoring of blood glucose
Study: NCT02901080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Stim AID cranial electrotherapy stimulation
Description: - 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: - Pregnancy test x 1 (day 1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety questionnaire
Description: - GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
Study: NCT00820846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pGA2/JS7 DNA vaccine
Description: 1 mL of pGA2/JS7 DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pGA2/JS7 DNA vaccine
Description: 1 mL of pGA2/JS7 DNA vaccine
Study: NCT02901080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: - EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Work and social questionnaire
Description: - WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep questionnaire
Description: - Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression questionnaire
Description: - PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life and financial questionnaire
Description: - CSRI questionnaire x 3 (day 1, week 12 and week 24)
Study: NCT05527106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA)
Description: Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline and Docosahexaenoic Acid (DHA)
Description: Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.
Study: NCT03766542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure with ventilatory support
Description: Positive airway pressure will be applied in the experimental group through a oronasal interface, in ventilatory support mode (Bi-level) with a fixed backup rate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure without ventilatory support
Description: Continuous positive airway pressure (CPAP) will be applied in the active comparator group through a oronasal interface.
Study: NCT04125992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal radial artery access in coronary angiography and angioplasty
Description: The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm radial artery access in coronary angiography and angioplasty
Description: The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis.
Study: NCT00006083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin
Description: Fragmin at 5000 IU injected subcutaneously daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo injected subcutaneously daily
Study: NCT00593736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
Study: NCT00820846

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of sodium chloride for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 mL of sodium chloride for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of sodium chloride for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62 vaccine
Description: 1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
Study: NCT02533856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ETOC
Description: Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
Study: NCT00820846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62 vaccine
Description: 1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62 vaccine
Description: 1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
Study: NCT03746457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: Individual counseling, group intervention, collective advocacy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention
Description: Individual counseling, group intervention, collective advocacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: Individual counseling, group intervention, collective advocacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: Individual counseling, group intervention, collective advocacy
Study: NCT06792331

Intervention type: PROCEDURE
Intervention: vNOTES high uterosacral ligament suspension
Description: Following the entry into the peritoneal cavity via apical colpotomy, a transvaginal retractor was inserted through the vaginal vault and the vaginal access platform was established. The ureters and uterosacral ligaments (USL) were identified via laparoscopic view. Bilateral nonabsorbable sutures were placed by the intermediate portions of the USL at the level of the ischial spines making up a total of 4 stitches (Figure 1). Then, the sutures were slightly weighed to verify proper placement. Then, the V-notes platform was removed and the peritoneum was closed. The aforementioned sutures were fixed to the ipsilateral cardinal ligament stump and the pubocervical fascia on the anterior wall. Finally, the previously mentioned nonabsorbable sutures were attached to the vaginal cuff and tied. Routine postoperative cystoscopy was performed.

Intervention type: PROCEDURE
Intervention: Laparoscopic lateral suspension
Description: The polypropylene mesh used had a width of 2.5 cm and a length of 25 cm. The vaginal cuff was suspended. Blunt dissection was applied to develop vesicovaginal and rectovaginal spaces. The middle part of the mesh was placed flatly in the vesicovaginal space, and fixed with non-absorbable sutures. An atraumatic laparoscopic instrument was inserted through skin incisions of approximately 2-3 mm approximately 3 cm above and 4 cm lateral to the anterior superior iliac spine, followed by perforation only of the aponeurosis of the external oblique muscle and retroperitoneal advancement of the instrument through the lateral abdominal wall. Under laparoscopic visualization, the instrument moved through the bilateral tension-free retroperitoneal tunnels created. The lateral arms of the mesh were secured bilaterally to the aponeurosis of the external oblique muscle and behind the anterior superior iliac spine. Finally, the peritoneum was closed.
Study: NCT00593736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
Study: NCT03049605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic therapy
Description: low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
Study: NCT00823095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
Study: NCT02265874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Habitrol
Description: Patch used daily for 28 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Habitrol
Study: NCT02871414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REST - Early Group
Description: Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
Study: NCT02251171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Study: NCT02390960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Cream
Description: Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Penile Plethysmography (RigiScan)
Description: During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penile Plethysmography (RigiScan)
Description: During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
Study: NCT06103019

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional complete denture
Description: conventional complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional complete denture
Description: conventional complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D complete denture
Description: 3D complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D complete denture
Description: 3D complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
Study: NCT04228107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication monitoring
Description: This is an observational study of medication use patterns. The propeller health device has reminders for controller medication use and gives feedback regarding medication use to the participant, their guardian and their asthma provider
Study: NCT06269575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE NUTRITION PROGRAM
Description: Safe nutrition program:~patient education, caregiver training, behavioral swallowing intervention, position, oral care, swallowing exercises, swallowing assessment
Study: NCT02871414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REST - Late Group
Description: Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
Study: NCT02859168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Induction
Description: Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Unplugged pulsed shortwave therapy
Description: Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
Study: NCT03047057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: IV Lidocaine infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: IV normal saline infusion
Study: NCT02617381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: assessing the sensitivity and specificity of a simple structured questionnaire
Study: NCT04101877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: 25 mg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection
Description: 40 mg/ml
Study: NCT02956239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermocoagulation (device)
Description: Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy (device)
Description: Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP (device)
Description: The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
Study: NCT05192109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overheard Speech
Description: New words are introduced with the child as a bystander rather directly taught.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Addressed Speech
Description: New words are introduced directly to the child by an experimenter.
Study: NCT02647814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salud al Día
Description: A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
Study: NCT01099553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Instructions to view an educational video about preparing for a colonoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Written instructions
Description: Written instructions on preparing for a colonoscopy
Study: NCT02859311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of therapy
Description: Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
Study: NCT03438747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-15L Bone Graft
Description: The investigational group will be treated with P-15L in an instrumented TLIF

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local autologous bone in a TLIF with Instrumentation
Description: The active control group will be treated local autologous bone in an instrumented TLIF